Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 40 min 11 sec ago

Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

Sun, 06/01/2019 - 07:00
VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019. “With our clinical, preclinical, and business development achievements in 2018, along with a robust balance sheet, we believe we are in a strong position to continue delivering on our corporate objectives in 2019 and beyond,” said Ali Tehrani, Ph.D.,

Generex Biotechnology Provides Update on NuGenerex Immuno-Oncology

Fri, 04/01/2019 - 10:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to provide an update on operational and strategic developments at NuGenerex Immuno-Oncology (previously Antigen Express), a wholly-owned subsidiary. The protocol for the Phase II clinical trial of pembrolizumab (Keytruda®) in combination with the AE37 Peptide Vaccine in patients with metastatic triple negative breast cancer is under review at the Institutional Review Board (IRB) with oversight of this NSAB

Grey Wolf Animal Health Announces the Acquisition of Veterinary Healthcare Solutions Inc.

Fri, 04/01/2019 - 08:00
TORONTO--(BUSINESS WIRE)--Grey Wolf Animal Health acquires Veterinary Healthcare Solutions. This combination creates a national presence across Canada and accelerates growth.

Total Safety Acquires Vantage Safety Services, Continues Its Canadian Expansion

Thu, 03/01/2019 - 10:00
HOUSTON--(BUSINESS WIRE)--Total Safety, the world’s leading provider of integrated safety services, announced today that it has strengthened its Canadian presence by acquiring Vantage Safety Services. Based in Clairmont, Alberta, Vantage Safety Services is a full-service industrial safety company providing services to all segments of the oil and gas industry. This acquisition continues Total Safety’s expansion and commitment to the Canadian market. It expands the company’s presence in the Grand

Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix

Thu, 03/01/2019 - 09:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCMKTS:GNBT) today announced that its partially, soon to be fully-owned subsidiary, Olaregen Therapeutix, Inc. has signed critical manufacturing agreements for Excellagen® with Collagen Solutions, a highly-regarded supplier of medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine applications, and with Berkshire Sterile Manufacturing (BSM), a state-of-the art, GMP fill/finish manufa

Genevant President & CEO Dr. Bo Rode Hansen to Present at Biotech Showcase 2019

Thu, 03/01/2019 - 09:00
BOSTON & BURNABY, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Genevant announced today that its President & CEO Dr. Bo Rode Hansen will present a corporate update at the Biotech Showcase 2019.

Forbius to Present at the 37th Annual J.P. Morgan Healthcare Conference

Wed, 02/01/2019 - 14:00
AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AVID100?src=hash" target="_blank"gt;#AVID100lt;/agt;--Forbius, a clinical-stage company developing biologics for the treatment of fibrosis and cancer, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. Mr. Tikhomirov’s presentation will take place Wednesday, January 9th at 11:30 am PST in Elizabethan D at the Westin St. Francis Hotel in San Francisco. About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer Forbi

Novanta to Present at the CJS Securities 19th Annual “New Ideas for the New Year” Institutional Investor Conference on Wednesday, January 9, 2019

Wed, 02/01/2019 - 12:00
BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the CJS Securities 19th Annual “New Ideas for the New Year” Institutional Investor Conference on Wednesday, January 9, 2019, in New York, NY. About Novanta Novanta is a leading global supplier of

SPG Media’s 25-Year-Old CEO Finds Success Telling the Story of Your Health's Future

Wed, 26/12/2018 - 17:00
TORONTO--(BUSINESS WIRE)--DNA tests are backbone of the emerging personalized health industry. As research develops, scientists discover more and more information that could be derived from DNA beyond ancestry. The DNA Co. has developed the most advanced functional genomics test in the world that may be able to tell you whether you may be a candidate for certain diseases such as diabetes and prostate cancer. The DNA Company has partnered up with award winning video production company, SPG Media

Devonian Health Group Announces 2018 Annual General Shareholder’s Meeting

Thu, 20/12/2018 - 09:00
QUEBEC--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage biopharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announced that its Annual General Shareholders’ Meeting will be held on Tuesday, January 29, 2019 at 15:30 p.m. EST at Château Bonne Entente, 3400 Chemin Sainte-Foy, City of Québec, Québec. Devonian also announced that it has set Monday, December

Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

Thu, 20/12/2018 - 08:00
SAN FRANCISCO & TEL AVIV, Israel--(BUSINESS WIRE)--Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. GVHD occurs when the transplanted donor cells a

Contextual Genomics Launches Improved FIND ITTM Assay and New FOLLOW ITTM Assay

Thu, 20/12/2018 - 08:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cancergenomics?src=hash" target="_blank"gt;#cancergenomicslt;/agt;--Contextual Genomics Inc., a leading Canadian cancer genomics company headquartered in Vancouver, Canada, announces that it has completed development of two new products: (i) an improved version of its FIND ITTM hotspot panel for detection of genomic mutations in solid tumour cancers, and (ii) its FOLLOW ITTM hotspot panel for detection of the same genomic mutations in blood plasma. Contextual Genomics’ FIND ITTM panel, a proprietary molecular hotspo

Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Wed, 19/12/2018 - 09:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST. The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of will also be archiv

Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises

Wed, 19/12/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises

Versant Ventures Raises $700 Million

Mon, 17/12/2018 - 09:00
SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Versant Ventures today announced an infusion of $700 million through two new funds. These include a primary global fund, Versant Venture Capital VII, which closed at its hard cap of $600 million. In addition, Versant raised $100 million for a Canadian companion fund called Versant Voyageurs I. Both funds exceeded their initial targets and were supported by existing investors and a select number of new

Versant Ventures Raises USD100 Million Canadian Fund

Mon, 17/12/2018 - 09:00
TORONTO & VANCOUVER, British Columbia & MONTREAL--(BUSINESS WIRE)--Versant Ventures today announced that it raised USD100 million for a Canadian fund called Versant Voyageurs I. Voyageurs will be deployed across five to eight startup companies with Canadian operations. The fund will be invested side by side with Versant’s primary biotech funds, including today’s newly announced USD600 million Versant Venture Capital VII. The objective of Voyageurs is to establish Canadian companies with the nec

Titan Medical Expands Global Patent Portfolio for Single-Port Robotic Surgery with Seven Grants and Notices of Allowance

Mon, 17/12/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (TSX:TMD) (Nasdaq:TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces seven new patent grants and notices of allowance related to its single-port robotic surgery technology, including patents covering multi-articulating instruments, robotic system control and user interfaces. Including these new patents and notice

AmorChem Spins out Its Muco-Adhesive Nanoparticle Delivery Platform into MyX Therapeutics, with 450,000$ Seed Investment.

Mon, 17/12/2018 - 09:00
MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MyXdelivery?src=hash" target="_blank"gt;#MyXdeliverylt;/agt;--AmorChem announces today the creation of MyX Therapeutics Inc, its sixth spin-off company focusing on MyX-001, a biodegradable muco-adhesive nanoparticle delivery platform, capable of sustained drug releases for ophthalmic use and other mucosa-based deliveries. All rights to the MyX-001 technology initially held by AmorChem have been transferred to MyX Therapeutics, with a first seed investment of 450,000$. This capital will allow MyX to clinch its first deals with co

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

Fri, 14/12/2018 - 10:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.” The Company's patent secures market exclusivity for its key product. Regentys ECMH™ is a novel application of extracellu

Tilray® Invests C$7.5M in Québec-Based Cannabis Producer ROSE Lifescience Inc.

Fri, 14/12/2018 - 09:00
NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced an investment in Québec-based cannabis producer, ROSE LifeScience Inc. (“ROSE”) and an exclusive sale, supply, distribution and marketing agreement between High Park Farms Ltd. (“High Park”), a wholly-owned subsidiary of Tilray, and ROSE. Tilray will subscribe for 41 Class “A” Common shares (12%) in the capital of ROSE for a subscription amount of C$7

Pages